5.41
Schlusskurs vom Vortag:
$5.06
Offen:
$5.11
24-Stunden-Volumen:
1.25M
Relative Volume:
0.96
Marktkapitalisierung:
$291.22M
Einnahmen:
$217.25M
Nettoeinkommen (Verlust:
$-50.92M
KGV:
-5.41
EPS:
-1
Netto-Cashflow:
$-100.85M
1W Leistung:
+17.86%
1M Leistung:
-26.39%
6M Leistung:
-61.49%
1J Leistung:
-75.05%
Prothena Corporation Plc Stock (PRTA) Company Profile
Firmenname
Prothena Corporation Plc
Sektor
Branche
Telefon
011-353-1-236-2500
Adresse
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Vergleichen Sie PRTA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PRTA
Prothena Corporation Plc
|
5.41 | 252.99M | 217.25M | -50.92M | -100.85M | -1.00 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-28 | Herabstufung | BofA Securities | Neutral → Underperform |
2025-05-27 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2025-05-27 | Herabstufung | Jefferies | Buy → Hold |
2025-05-27 | Herabstufung | Oppenheimer | Outperform → Perform |
2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
2024-01-30 | Herabstufung | BofA Securities | Buy → Neutral |
2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
2023-04-24 | Eingeleitet | SVB Securities | Outperform |
2023-01-27 | Eingeleitet | Piper Sandler | Overweight |
2022-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-09-28 | Hochstufung | BofA Securities | Neutral → Buy |
2021-11-19 | Eingeleitet | JMP Securities | Mkt Outperform |
2021-06-18 | Hochstufung | BofA Securities | Underperform → Neutral |
2021-06-08 | Bestätigt | Oppenheimer | Outperform |
2021-05-26 | Eingeleitet | Citigroup | Buy |
2021-02-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2021-02-12 | Hochstufung | Jefferies | Hold → Buy |
2021-02-02 | Hochstufung | BTIG Research | Neutral → Buy |
2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
2020-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
2019-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
2018-05-21 | Herabstufung | Barclays | Equal Weight → Underweight |
2018-04-23 | Herabstufung | Jefferies | Buy → Hold |
2018-04-05 | Bestätigt | Barclays | Overweight |
2017-11-20 | Herabstufung | Wedbush | Outperform → Neutral |
2017-09-29 | Bestätigt | BTIG Research | Buy |
2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
2017-07-11 | Eingeleitet | Jefferies | Buy |
2017-04-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
2017-04-12 | Eingeleitet | Piper Jaffray | Overweight |
2017-03-02 | Eingeleitet | Instinet | Buy |
2016-12-21 | Eingeleitet | SunTrust | Buy |
2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
2016-08-04 | Bestätigt | Barclays | Overweight |
2016-05-13 | Eingeleitet | Barclays | Overweight |
2016-02-19 | Bestätigt | Wedbush | Outperform |
2016-01-21 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Prothena Corporation Plc Aktie (PRTA) Neueste Nachrichten
Prothena Co. plc (NASDAQ:PRTA) Short Interest Update - Defense World
Bank of America Corp DE Purchases 36,944 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
(PRTA) Technical Data - news.stocktradersdaily.com
Millennium Management LLC Has $1.70 Million Holdings in Prothena Co. plc (NASDAQ:PRTA) - Defense World
PROTHENA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Prothena Corporation plc To Contact The Firm - ACCESS Newswire
ProShare Advisors LLC Buys 3,312 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Chardan Capital Decreases Earnings Estimates for Prothena - Defense World
Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails - MSN
FY2027 EPS Estimates for Prothena Decreased by HC Wainwright - Defense World
Prothena (NASDAQ:PRTA) Given “Underperform” Rating at Bank of America - Defense World
Bank of America Reiterates “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World
Bank of America Reaffirms “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World
Prothena (NASDAQ:PRTA) Receives Underperform Rating from Bank of America - Defense World
The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts - simplywall.st
BofA cuts Prothena stock rating, slashes target to $4 By Investing.com - Investing.com Nigeria
Prothena Corp (PRTA) Sees Downgrade and Price Target Cut by B of A Securities | PRTA Stock News - GuruFocus
Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform - Insider Monkey
BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target - marketscreener.com
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | P - GuruFocus
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | PRTA Stock News - GuruFocus
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down - MSN
Prothena (PRTA) Downgraded by BofA Analyst with Lower Price Targ - GuruFocus
Prothena (NASDAQ:PRTA) Price Target Lowered to $81.00 at Piper Sandler - Defense World
Prothena (NASDAQ:PRTA) Price Target Cut to $29.00 by Analysts at JMP Securities - Defense World
Prothena (NASDAQ:PRTA) Lowered to Hold Rating by Jefferies Financial Group - Defense World
Prothena (NASDAQ:PRTA) Given New $14.00 Price Target at HC Wainwright - Defense World
Traders Purchase High Volume of Put Options on Prothena (NASDAQ:PRTA) - Defense World
Oppenheimer cuts Prothena stock rating after trial setback By Investing.com - Investing.com Nigeria
Prothena (PRTA) Shares Plunge After Key Trial Setback - GuruFocus
Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place (PRTA) - Seeking Alpha
Peninsula biotech Prothena falters — again — and layoffs are on the waySan Francisco Business Times - The Business Journals
Prothena Shares Fall, Stock Downgraded by Multiple Research Firms After Birtamimab Development Discontinued - marketscreener.com
Prothena Corp (PRTA) Downgraded by Oppenheimer | PRTA Stock News - GuruFocus
Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results - Insider Monkey
Prothena stock hits 52-week low amid downgrades (PRTA:NASDAQ) - Seeking Alpha
Prothena Corp (PRTA) Sees Target Price Reduction by Piper Sandle - GuruFocus
Piper Sandler cuts Prothena stock target to $81 from $110 By Investing.com - Investing.com UK
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Cantor Fitzgerald cuts Prothena stock rating to Neutral By Investing.com - Investing.com UK
Prothena Corp (PRTA) Target Price Slashed by JMP Securities | PRTA Stock News - GuruFocus
Prothena (PRTA) Downgraded Following Unsuccessful Phase 3 Trial - GuruFocus
Expert Outlook: Prothena Corp Through The Eyes Of 5 Analysts - Benzinga
Prothena Corp (PRTA) Analyst Update: Price Target Significantly Lowered | PRTA Stock News - GuruFocus
Why Is Prothena Stock Trading Lower On Tuesday? - Benzinga
Prothena Corp (PRTA) Price Target Lowered by HC Wainwright & Co. - GuruFocus
Jefferies Downgrades Prothena to Hold From Buy, Adjusts Price Target to $6 From $32 - marketscreener.com
Prothena Corp (PRTA) Price Target Lowered by HC Wainwright & Co. | PRTA Stock News - GuruFocus
Prothena stock price target cut to $14 at H.C. Wainwright By Investing.com - Investing.com UK
Finanzdaten der Prothena Corporation Plc-Aktie (PRTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prothena Corporation Plc-Aktie (PRTA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
EcoR1 Capital, LLC | 10% Owner |
May 06 '25 |
Sale |
7.64 |
1,984,053 |
15,164,712 |
5,304,596 |
EcoR1 Capital, LLC | 10% Owner |
May 05 '25 |
Sale |
8.11 |
977,693 |
7,930,166 |
7,288,649 |
SCULLY WILLIAM P | 10% Owner |
Jan 14 '25 |
Buy |
12.79 |
100,000 |
1,279,040 |
735,993 |
SCULLY WILLIAM P | 10% Owner |
Dec 18 '24 |
Buy |
13.93 |
73,436 |
1,022,670 |
1,297,693 |
SCULLY WILLIAM P | 10% Owner |
Dec 31 '24 |
Buy |
13.01 |
32,000 |
416,393 |
650,193 |
SCULLY WILLIAM P | 10% Owner |
Dec 20 '24 |
Buy |
15.91 |
2,000 |
31,813 |
618,693 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):